NeoGenomics (NASDAQ:NEO) Stock Dropped to Hold by Wall Street Zen

Wall Street Zen lowered shares of NeoGenomics (NASDAQ:NEO) from a buy rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

Other research analysts have also recently issued research reports about the company. Benchmark boosted their price objective on NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Zacks Research downgraded NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Craig Hallum reaffirmed a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research report on Wednesday, July 29th. BTIG Research reiterated a “buy” rating and set a $28.00 target price on shares of NeoGenomics in a research note on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, October 12th. Eight equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.88.

NeoGenomics Trading Down 3.1%

Shares of NEO stock opened at $17.38 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 3.35 and a current ratio of 3.53. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -69.52 and a beta of 1.79. NeoGenomics has a 52-week low of $7.07 and a 52-week high of $20.15. The company has a 50-day simple moving average of $17.68 and a two-hundred day simple moving average of $12.82.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Wednesday, October 28th. The medical research company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. The firm had revenue of $209.25 million for the quarter, compared to analysts’ expectations of $206.70 million. NeoGenomics had a negative net margin of 4.10% and a negative return on equity of 0.99%. The company’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.03 EPS. Research analysts anticipate that NeoGenomics will post -0.09 EPS for the current fiscal year.

Hedge Funds Weigh In On NeoGenomics

Institutional investors have recently bought and sold shares of the company. Root Financial Partners LLC purchased a new stake in NeoGenomics in the 3rd quarter worth about $29,000. GAMMA Investing LLC raised its stake in NeoGenomics by 30.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,782 shares of the medical research company’s stock valued at $51,000 after acquiring an additional 644 shares during the period. Farther Finance Advisors LLC raised its stake in NeoGenomics by 117.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,701 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 917 shares during the period. First Light Asset Management LLC raised its stake in NeoGenomics by 26.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock valued at $179,158,000 after acquiring an additional 2,549,545 shares during the period. Finally, WINTON GROUP Ltd purchased a new stake in NeoGenomics during the second quarter valued at about $925,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Key NeoGenomics News

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q3 results exceeded expectations. NeoGenomics reported third-quarter revenue of approximately $209 million, up 11.3% year over year, while earnings per share of $0.07 topped the $0.06 consensus estimate. NeoGenomics third-quarter earnings results
• Positive Sentiment: Management raised its full-year outlook. The company increased 2026 revenue guidance to $807 million-$809 million, signaling continued demand for its cancer-testing and laboratory-services business. The improved outlook was highlighted alongside the earnings beat. NeoGenomics raises 2026 guidance
• Positive Sentiment: Analyst support remains strong. BTIG Research reaffirmed its “Buy” rating and maintained a $28 price target, implying substantial upside from recent trading levels. Investors also continue to assess whether the earnings beat and higher guidance leave the stock attractively valued. BTIG Research rating
• Neutral Sentiment: CEO transition planned for January 2027. NeoGenomics disclosed that its chief executive transition is expected early next year. The change could eventually support new strategic initiatives, but investors may initially seek more clarity on succession and execution. NeoGenomics 2026 third-quarter earnings presentation
• Negative Sentiment: Profitability remains a concern. Although adjusted quarterly earnings beat estimates, the company continues to face pressure from weak reported profitability, with a negative net margin and analysts expecting a full-year loss. This may be limiting the stock’s reaction to the stronger revenue outlook.

About NeoGenomics

NeoGenomics, Inc (NASDAQ: NEO) is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company’s services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.